M Shayne Gallaway1, Bin Huang2,3, Quan Chen3, Thomas C Tucker3,4, Jaclyn K McDowell3, Eric Durbin3,5, Sherri L Stewart6, Eric Tai6. 1. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health, 4770 Buford Highway, MS F76, Atlanta, GA, 30341, Georgia. lnx7@cdc.gov. 2. Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, KY, USA. 3. Kentucky Cancer Registry, College of Medicine, University of Kentucky, Lexington, KY, USA. 4. Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY, USA. 5. Division of Biomedical Informatics, College of Medicine, University of Kentucky, Lexington, KY, USA. 6. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health, 4770 Buford Highway, MS F76, Atlanta, GA, 30341, Georgia.
Abstract
PURPOSE: To examine smoking and use of smoking cessation aids among tobacco-associated cancer (TAC) or non-tobacco-associated cancer (nTAC) survivors. Understanding when and if specific types of cessation resources are used can help with planning interventions to more effectively decrease smoking among all cancer survivors, but there is a lack of research on smoking cessation modalities used among cancer survivors. METHODS: Kentucky Cancer Registry data on incident lung, colorectal, pancreatic, breast, ovarian, and prostate cancer cases diagnosed 2007-2011, were linked with health administrative claims data (Medicaid, Medicare, private insurers) to examine the prevalence of smoking and use of smoking cessation aids 1 year prior and 1 year following the cancer diagnosis. TACs included colorectal, pancreatic, and lung cancers; nTAC included breast, ovarian, and prostate cancers. RESULTS: There were 10,033 TAC and 13,670 nTAC survivors. Smoking before diagnosis was significantly higher among TAC survivors (p < 0.0001). Among TAC survivors, smoking before diagnosis was significantly higher among persons who: were males (83%), aged 45-64 (83%), of unknown marital status (84%), had very low education (78%), had public insurance (89%), Medicaid (85%) or were uninsured (84%). Smoking cessation counseling and pharmacotherapy were more common among TAC than nTAC survivors (p < 0.01 and p = 0.05, respectively). DISCUSSION: While smoking cessation counseling and pharmacotherapy were higher among TAC survivors, reducing smoking among all cancer survivors remains a priority, given cancer survivors are at increased risk for subsequent chronic diseases, including cancer. Tobacco cessation among all cancer survivors (not just those with TAC) can help improve prognosis, quality of life and reduce the risk of further disease. Health care providers can recommend for individual, group and telephone counseling and/or pharmacotherapy recommendations. These could also be included in survivorship care plans.
PURPOSE: To examine smoking and use of smoking cessation aids among tobacco-associated cancer (TAC) or non-tobacco-associated cancer (nTAC) survivors. Understanding when and if specific types of cessation resources are used can help with planning interventions to more effectively decrease smoking among all cancer survivors, but there is a lack of research on smoking cessation modalities used among cancer survivors. METHODS:Kentucky Cancer Registry data on incident lung, colorectal, pancreatic, breast, ovarian, and prostate cancer cases diagnosed 2007-2011, were linked with health administrative claims data (Medicaid, Medicare, private insurers) to examine the prevalence of smoking and use of smoking cessation aids 1 year prior and 1 year following the cancer diagnosis. TACs included colorectal, pancreatic, and lung cancers; nTAC included breast, ovarian, and prostate cancers. RESULTS: There were 10,033 TAC and 13,670 nTAC survivors. Smoking before diagnosis was significantly higher among TAC survivors (p < 0.0001). Among TAC survivors, smoking before diagnosis was significantly higher among persons who: were males (83%), aged 45-64 (83%), of unknown marital status (84%), had very low education (78%), had public insurance (89%), Medicaid (85%) or were uninsured (84%). Smoking cessation counseling and pharmacotherapy were more common among TAC than nTAC survivors (p < 0.01 and p = 0.05, respectively). DISCUSSION: While smoking cessation counseling and pharmacotherapy were higher among TAC survivors, reducing smoking among all cancer survivors remains a priority, given cancer survivors are at increased risk for subsequent chronic diseases, including cancer. Tobacco cessation among all cancer survivors (not just those with TAC) can help improve prognosis, quality of life and reduce the risk of further disease. Health care providers can recommend for individual, group and telephone counseling and/or pharmacotherapy recommendations. These could also be included in survivorship care plans.
Authors: J P Mackenbach; G J Borsboom; W J Nusselder; C W Looman; C T Schrijvers Journal: J Epidemiol Community Health Date: 2001-09 Impact factor: 3.710
Authors: Ellen R Gritz; Michelle Cororve Fingeret; Damon J Vidrine; Amy B Lazev; Netri V Mehta; Gregory P Reece Journal: Cancer Date: 2006-01-01 Impact factor: 6.860
Authors: Karen Emmons; Frederick P Li; John Whitton; Ann C Mertens; Raymond Hutchinson; Lisa Diller; Leslie L Robison Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 50.717
Authors: Sophia J Luo; Eunji Choi; Jacqueline V Aredo; Lynne R Wilkens; Martin C Tammemägi; Loïc Le Marchand; Iona Cheng; Heather A Wakelee; Summer S Han Journal: JNCI Cancer Spectr Date: 2021-08-23
Authors: Eunji Choi; Sophia J Luo; Jacqueline V Aredo; Leah M Backhus; Lynne R Wilkens; Chloe C Su; Joel W Neal; Loïc Le Marchand; Iona Cheng; Heather A Wakelee; Summer S Han Journal: J Natl Cancer Inst Date: 2022-04-11 Impact factor: 13.506